Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Plan B status

This article was originally published in The Tan Sheet

Executive Summary

Barr Labs expects to receive an "approvable" letter from FDA before a Feb. 20 PDUFA deadline for switching its emergency contraceptive pill Plan B (levonorgestrel .75 mg) from prescription to over-the-counter status. During a Feb. 5 earnings call, execs confirmed Barr's R&D group has met recently with the agency regarding the switch application. The Pomona, N.Y.-based firm also maintains the product will be successful for Barr even if it stays an Rx drug. Barr expects to complete the purchase of Plan B developer Women's Capital Corp. within the next two weeks; the firm signed a letter of intent to purchase WCC in October 2003 (1"The Tan Sheet" Oct. 6, 2003, p. 3)...

You may also be interested in...

Barr Plans Move To OTC Market With Plan B Emergency Contraceptive

Barr Laboratories will continue to pursue an Rx-to-OTC switch for the emergency contraceptive Plan B following its planned acquisition of the product

Moderna Stands Alone With Single-Antigen Approach To COVID-19 Vaccine

Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.

Kansas City TCM Firm Persists With COVID-19 Claims Following US Regulators' Warning

Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts